IMR Press / EJGO / Volume 39 / Issue 3 / DOI: 10.12892/ejgo3939.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
The impact of adjuvant therapy on survival in patients with FIGO Stage IB Grade 3 endometrial cancer
Show Less
1 Division of Gynecologic Oncology, Karmanos Cancer Institute, Mclaren Flint, MI, USA
2 Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
3 Division of Gynecologic Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
4 Department of Family Medicine and Public Health Services and Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
Eur. J. Gynaecol. Oncol. 2018, 39(3), 422–429; https://doi.org/10.12892/ejgo3939.2018
Published: 10 June 2018
Abstract

Purpose of Investigation: To examine the patterns of care, predictors, and impact of adjuvant therapy on survival in patients with Stage IB Grade 3 endometrial cancer. Materials and Methods: The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was used to identify women 65 years or older diagnosed with Stage IB Grade 3 endometrial cancer from 1991 through 2007. Results: A total of 624 women were included. Adjuvant external beam radiation therapy (EBRT) was administered in 54% of the patients, while 22% received vaginal brachytherapy (VBT), and 7% received chemotherapy. In Cox-proportional hazards regression models, neither EBRT (HR: 0.94; 95% CI; 0.71–1.22), nor VBT (HR: 0.84; 95% CI: 0.60–1.17), or chemotherapy (HR: 1.30: 95% CI; 0.64–2.66) was associated with reduced mortality in patients with Stage IB Grade 3 endometrial cancer. Conclusion: Although commonly used; neither adjuvant radiation nor chemotherapy significantly improves survival in patients with Stage IB Grade 3 endometrial cancer.
Keywords
Endometrial cancer
Adjuvant therapy
Survival
Share
Back to top